Renal magnesium handling is not subject to developmental programming

Saleh H Alwasel1, Vandana Sahajpal, Nick Ashton

  • 1Fetal Programming of Diseases Research Chair, College of Science, King Saud University, Riyadh, Saudi Arabia. salwasel@ksu.edu.sa

Developmental programming of hypertension, induced by maternal protein restriction, is associated with enhanced urinary excretion of sodium and calcium in the rat. Although calcium and magnesium are reabsorbed via different pathways, renal calcium excretion often parallels magnesium output. Accordingly, the aim of the current study was to assess magnesium handling in rats exposed to a low-protein (LP) diet in utero. Wistar rats were fed a control (18%) or LP (9%) diet throughout pregnancy; offspring were weaned onto standard rat chow and studied at 4 weeks of age. Renal clearance measurements were made in both volume expanded and euvolaemic anaesthetised rats; 24-hour magnesium turnover was also assessed in conscious animals. Plasma and total body magnesium content were measured. Total (U(Mg)V) and fractional excretion (FE(Mg)) of magnesium did not differ between control and LP rats under any of the experimental conditions. Neither plasma nor total body magnesium content differed between control and LP rats. Thus the hypercalciuria of LP rats is not mirrored by an increase in renal magnesium excretion. These data suggest that renal magnesium handling is not affected by developmental programming.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...